Nyhet -

The uniqueness of Medicon Valley Alliance

Medicon Valley Alliance (MVA) is a non-profit membership organisation in the Danish-Swedish life science cluster Medicon Valley. They also have the distinction of being the only bi-national cluster region in the Nordics.

All cluster formations within Life Science collaborate with other actors nationally and internationally, but MVA has built an entire life science cluster across two leading life science countries.

“MVA’s mission is to be the leading life science cluster region in the European Union. Life Science is an industry that has developed explosively over the past decade in the region”, says MVA CEO Anette Steenberg.

Creating an ecosystem

The Medicon Valley region in Southern Sweden and Eastern Denmark embraces more than 50,000 life science jobs, 5 life science parks, 9 universities and 28 hospitals.

There are over 300 member companies of MVA, and is constantly expanding with more members from both academia and industry. Together with them, MVA aims to create an ecosystem of life science collaborations, knowledge sharing, attracting investments and talent all contributing to building this region into one of Europe’s most vibrant and competitive life science clusters.

“However, we would also like to look outside Medicon Valley and include more of the Nordic regions in our future collaborations”, Anette notes, and it seems that vision is becoming a reality as the new partnership between Genomic Medicine Sweden and Danish National Genome Center was announced this month.

MVA noted that it is the Medicon Valley Alliance spirit exemplified with Medicon Valley and Stockholm-Uppsala as the beacons of Nordic life science visible to the world.

Constellation of great international interest

In terms of competence and knowledge, Medicon Valley has already come a long way on that front. They are not limited by geographical boundaries, nor by disciplinary boundaries.

“To support collaboration and development throughout the region, we have lots of events during the year,” says Anette. “Morning meetings, workshops, in many different themes that highlight our region’s different strengths and serves as meeting and marketplaces for life science regionally, nationally and globally.”

MVA have several concrete examples of strategic and cross-border projects in fertility treatment (Reprounion project), microbiology (Microbiome signature project) and diabetes (DiaUnion project), to name a few.

Anette’s vision for MVA concludes by explaining how they are seeing, “fantastic academic and industrial skills along with strong public support on both sides of the strait. If we can continue to facilitate increased collaboration and build on common strengths across the border and between academia, public and private sector, we will pave the way for Medicon Valley as world class life science cluster competing with the very best not only in Europe, but also globally.

Relaterade länkar

Ämnen

  • Ekonomi, finans

Kategorier

  • medicon valley life science

Regioner

  • Skåne

Kontakter

  • Anette Steenberg Pressefoto
    Licens:
    All rights reserved

Relaterat innehåll

  • TATAA Biocenter to offer GLP services to developers of cell and gene therapies across the world

    TATAA Biocenter was first to develop PCR technology in Sweden and was also a pioneer by offering covid tests at the very beginning of the outbreak of the pandemic. TATAA Biocenter is now building Europe’s most modern laboratory for molecular analyses in Gothenburg.
    The team behind TATAA Biocenter has worked with molecular analyses for over 30 years. The company was established around 20 years a

  • Founding Partner Mölnlycke Health Care will move to GoCo in 2024

    Mölnlycke Health Care stands for innovation and quality. This is also a strongly contributing reason why all Gothenburg-based operations within Mölnlycke will move to GoCo Health Innovation City at the end of 2024.
    All stakeholders in medicine and health technology have a comprehensive responsibility to help healthcare reach the next level with better products and more effective solutions.

  • A new giant is born with GoCo Health Innovation City

    Within a few years, between 8,000 and 10,000 jobs will be created in the GoCo Health Innovation City.
    Just like the BioVentureHub and the innovation environment there, GoCo Health Innovation City has been created on the initiative of AstraZeneca.
    In the beginning there was a giant
    It started with the pharmaceutical giant, AstraZeneca looking to sell some of their land connecting to thei

  • A winning team for In Vivo Research Services

    Based in Medicon Village, IVRS (In Vivo Research Services) is a preclinical CRO which provides innovating drug validation studies both in vitro and in vivo allowing to accelerate the drug development process for unmet needs related to severe human diseases.
    IVRS specialises in providing 3D-images with the aim to characterise disease progression; follow the therapeutic effect throughout the comp

  • Medeon Science Park continues its journey of expansion

    Medeon Science Park has a strong focus on the expansion that began over 18 months ago, and which now enables new establishments in the park. After a number of stages of new construction and remodelling, there is now space available for the successful growing companies expanding in the park, but also for completely new establishments.
    A stimulating business climate with an ideal location offers

  • Novel treatments for aggressive cancer based on a unique target

    The discovery of the unique target integrin α10β1 may change the outcome of cancer treatment for thousands of patients across the world. Tumor-targeting antibodies for the treatment of aggressive cancers are currently being developed by Targinta, a subsidiary of biopharma company Xintela in Lund.
    Targinta is the oncology subsidiary of the stem cell company Xintela. Both Xintela and Targinta ar

  • Making the impossible possible

    Diagonal Bio AB (Diagonal) is a biotech company that seeks to do what was once thought impossible – create a universal diagnostic platform which is quick, accurate, cost-effective and able to test multiple samples in parallel. The company was founded in Medicon Village in Lund in 2020, with a vision to limit the spread of infectious disease world-wide.
    Diagonal plan to realise the vision by cr

  • Bioneer helps life science with R&D

    The Contract Research Organisation Bioneer acts as an external R&D department for the life science ecosystem of companies involved in therapeutic development. The company is seeing substantial growth partly driven by its impressive journey as a specialty-CRO for recombinant protein solutions.
    The specialty-CRO Bioneer has consolidated its role as R&D partner to the life science industr

  • Stem cell product XSTEM in clinical studies

    The Swedish biopharma company Xintela is receiving a lot of attention for its stem cell product platform XSTEMÒand its stem cell therapies in development.
    XSTEM is now in clinical development for the treatment of knee osteoarthritis and difficult-to-heal venous leg ulcers.
    Over the last several years Xintela has worked extensively on preclinical development in three core areas: osteoarthrit